Compositions and methods for improving cardiac structure and/or function

Abstract

Compositions and methods for improving cardiac structure and/or function in subjects in need thereof. The methods include administering to a subject a succinate dehydrogenase inhibitor in an amount and for a time effective to elicit an improvement in cardiac structure and/or function. The subjects include subjects suffering from cardiac damage, such as damage resulting from myocardial infarction or other cardiac events. Improvements in cardiac function include one or more of an increase in cardiomyocyte proliferation, an increase in ejection fraction, an increase in fractional shortening, a decrease in left ventricle internal diameter diastole, and a decrease in left ventricle internal diameter systole. Improvements in cardiac structure include one or more of decreased fibrosis, an increase in myocardial thickness, an increase in coronary artery formation, an increase in capillary density, an increase in revascularization, and a decrease in myocardial lesion size. Compositions for performing the methods are provided.

1 - 20 . (canceled) 
     
     
         21 . A method of improving cardiac structure and/or function in a subject, the method comprising administering a succinate dehydrogenase inhibitor to the subject at least 90 minutes after a cardiac event selected from the group consisting of cardiac ischemia, cardiac ischemia-reperfusion, myocardial infarction, and any combination thereof, wherein the succinate dehydrogenase inhibitor is administered in an amount and for a time effective to elicit an improvement in cardiac structure and/or function. 
     
     
         22 . The method of  claim 21 , wherein the subject has a myocardial lesion. 
     
     
         23 . The method of  claim 21 , wherein the subject has a myocardial lesion selected from the group consisting of fibrosis, decreased myocardial thickness, a myocardial infarct, and any combination thereof. 
     
     
         24 . The method of  claim 21 , wherein the subject has a myocardial infarct. 
     
     
         25 . The method of  claim 21 , wherein the administering comprises administering the succinate dehydrogenase inhibitor to the subject within 6 weeks after the cardiac event. 
     
     
         26 . The method of  claim 21 , wherein the administering comprises administering the succinate dehydrogenase inhibitor to the subject at least 1 day after the cardiac event. 
     
     
         27 . The method of  claim 26 , wherein the administering comprises administering the succinate dehydrogenase inhibitor to the subject within 6 weeks after the cardiac event. 
     
     
         28 . The method of  claim 21 , wherein the administering comprises administering the succinate dehydrogenase inhibitor to the subject at least 3 days after the cardiac event. 
     
     
         29 . The method of  claim 28 , wherein the administering comprises administering the succinate dehydrogenase inhibitor to the subject within 6 weeks after the cardiac event. 
     
     
         30 . The method of  claim 21 , wherein the administering comprises administering the succinate dehydrogenase inhibitor to the subject over a period of time at least 90 minutes after the cardiac event, wherein the period of time spans at least 1 day. 
     
     
         31 . The method of  claim 30 , wherein the period of time comprises a point in time within 6 weeks after the cardiac event. 
     
     
         32 . The method of  claim 30 , wherein the period of time spans at least 3 days. 
     
     
         33 . The method of  claim 32 , wherein the period of time comprises a point in time within 6 weeks after the cardiac event. 
     
     
         34 . The method of  claim 33 , wherein the succinate dehydrogenase inhibitor is intermittently administered to the subject over the period of time. 
     
     
         35 . The method of  claim 21 , wherein the succinate dehydrogenase inhibitor is administered in an amount and for a time effective to elicit an improvement in cardiac function selected from the group consisting of an increase in cardiomyocyte proliferation, an increase in ejection fraction, an increase in fractional shortening, a decrease in left ventricle internal diameter diastole, a decrease in left ventricle internal diameter systole, and any combination thereof. 
     
     
         36 . The method of  claim 21 , wherein the succinate dehydrogenase inhibitor is administered in an amount and for a time effective to elicit an improvement in cardiac structure selected from the group consisting of decreased fibrosis, an increase in myocardial thickness, an increase in coronary artery formation, an increase in capillary density, an increase in revascularization, a decrease in myocardial lesion size, and any combination thereof. 
     
     
         37 . The method of  claim 21 , wherein the succinate dehydrogenase inhibitor comprises a succinate-analog inhibitor. 
     
     
         38 . The method of  claim 35 , wherein the succinate-analog inhibitor comprises a malonate compound. 
     
     
         39 . The method of  claim 21 , wherein:
 the subject has a myocardial lesion;   the succinate dehydrogenase inhibitor is administered in an amount and for a time effective to elicit an improvement selected from the group consisting of an improvement in cardiac function and an improvement in cardiac structure, wherein:
 the improvement in cardiac function is selected from the group consisting of an increase in cardiomyocyte proliferation, an increase in ejection fraction, an increase in fractional shortening, a decrease in left ventricle internal diameter diastole, a decrease in left ventricle internal diameter systole, and any combination thereof; and 
 the improvement in cardiac structure is selected from the group consisting of decreased fibrosis, an increase in myocardial thickness, an increase in coronary artery formation, an increase in capillary density, an increase in revascularization, a decrease in myocardial lesion size, and any combination thereof; and 
   the administering comprises administering the succinate dehydrogenase inhibitor to the subject over a period of time at least 90 minutes after the cardiac event, wherein the period of time spans at least 3 days and comprises a point in time within 6 weeks after the cardiac event.   
     
     
         40 . The method of  claim 39 , wherein the period of time spans at least two weeks.